Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and ...

The FDA has approved Simtriyo, a nonstimulant daily pill for ADHD in children, teens, and adults. Here’s more on potential ...

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of ...

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the ...

Centanafadine XR demonstrated efficacy in improving symptoms in adults with attention-deficit/hyperactivity disorder and comorbid anxiety.

The U.S. FDA has approved centanafadine (Simtriyo), the first oral triple reuptake inhibitor for the treatment of attention ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of ...

If you've spent any time on ADHD corners of social media lately, you've likely been barraged by posts about "low dopamine," "dopamine-seeking," and "dopamine detoxes" in ADHD. While these seem to be ...

IT’S no secret that ADHD diagnoses are soaring, with nearly three million people in the UK living with the condition. Ant ...

"You pull a weed and the bed looks better in thirty seconds. You plant something and ten days later it's there," writes Cassandra Danhiez (@cassandradanhiez on social media) in her caption. She ...